alexa ̔Mirtazapine-Galantamine Combo̓ Tackles Behavioral Facets in Autism | Open Access Journals
ISSN: 2165-7890
Autism-Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

̔Mirtazapine-Galantamine Combo̓ Tackles Behavioral Facets in Autism

Ahmed Naguy1* and Ali Al Tajali2

1Child and Adolescent Psychiatrist, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait

2General Adult Psychiatrist, Head of Neuromodulation Unit, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait

*Corresponding Author:
Ahmed Naguy
CAP Unit, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait
Tel: +965-65541937
E-mail:
ahmednagy@hotmail.co.uk

Received: June 21, 2015; Accepted: July 20, 2015; Published: July 27, 2015

Citation: Naguy N, Tajali AA (2015) ?Mirtazapine-Galantamine Combo? Tackles Behavioral Facets in Autism. Autism Open Access 5:145. doi:10.4172/2165-7890.1000145

Copyright: © 2015 Naguy A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Visit for more related articles at Autism-Open Access

Keywords

Autism; Challenging; Behaviors; Mirtazapine; Galantamine

To The Editor

Autism Spectrum Disorders (ASD) are associated with a host of challenging behaviors that constitute a focus of clinical attention and a target for psychopharmacologic interventions [1]. Only Risperidone and Aripiprazole are FDA-approved to address these behavioral facets once psychological and educational approaches (e.g. Applied Behavioral Analysis, Sensory Integration) are ineffective, inaccessible, or, unaffordable [2]. Moreover, no single drug is currently approved to alter core symptoms of ASD. These behaviors include, inter alia, ADHD-like symptoms, tics and stereotypies, auto- and hetero-aggression, irritability and mood and anxiety symptoms, disturbed eating and sleeping patterns, and sexually-inappropriate behaviors [1].

Unfortunately, the use of these atypical antipsychotics is fraught with a multitude of cardio-metabolic and neurologic syndromes [3]. This calls for novel psychotropic agents that are both effective and tolerable.

Mirtazapine is atypical antidepressant with unique mechanism of action, namely; Noradrenergic-Specific Serotonergic Antidepressant (NaSSA); blocking α2 auto&hetero-receptors, thus increasing norepinephrine, also blocking 5HT2&3 receptors, as well as H1 receptors.

Galantamine is anti-dementia specific acetylcholinestrase inhibitor (AchE-i) and allosteric ligand at nicotinic acetylcholine receptors (nAchR).

Here, we are reporting on a case of an adolescent with ASD, where ‘Mirtazapine-Galantamine cocktail’ brought about a significant improvement in the behavioral domains and strikingly, hit some of the core social features. This was achieved with great tolerability.

A 14-year-old Kuwaiti youngster, eldest of five sibs, a product of elective Caesarean Section, emanating from a consanguineous monogamous family, attending special schooling, long diagnosed as ASD/ID (Intellectual Disability)/Epilepsy, maintained on Valproate for seizure control, was escorted by his parents for escalating behavioral dyscontrol, notably irritability, aggression, hyperactivity, fitful sleep and socially flouting over sexualized behaviors. Medical and environmental causation of this behavioral decompensation were meticulously ruled out. He couldn’t tolerate a trial on Risperidone where he developed recurrent torticollis and oculogyric crisis. He failed a 6-week trial on 15 mg/d Aripiprazole. Clonidine was also tried at 300 µg/d but prematurely aborted for severe hypotension (80/50) and symptomatic bradycardia (50/min). Atomoxetine, for hyperactivity was instituted, uptitrated to 40 mg/d over 8 weeks, but, without clinically meaningful response. Ecitalopram at 10 mg/d, for 4 weeks, was introduced for aggression, but to no avail. We suggested a trial with Mirtazapine as data from the literature support its use for sexually-inappropriate behaviors in ASD, and also to help with sleep and irritability. We went to 45 mg/d over 4 weeks. Sleep improved markedly, irritability diminished significantly and most importantly, sexual behaviors were greatly tamed. Both frequency and severity of aggression became obviously less. This was well-sustained at follow-ups W-6, 8, and 12. We, then, opined to embark on a trial of Galantamine, as burgeoning evidence from literature favors its use for both core and behavioral symptom sets of ASD. We dosed it at 8 mg/d for 4 weeks, then up to 16 mg/d (in 2 divided doses). Strikingly, hyperactivity noticeably decreased, but, most importantly, better eye contact, vocalizations, gestures and social relatedness were observed. This was plateaued at follow-ups W-6, 8, and 12. No pharmacokinetic drug interactions reported with this combination. No side effects, of significance, were noted. These findings were objectified on Aberrant Behavior Checklist (ABCL) and Krug’s Autism Behavior Checklist (ABC). Medications Chart is portrayed in table (1).

Drug Comment
Risperidone Extrapyramidal Side Effects
Aripiprazole Ineffective
Clonidine Hypotension and bradycardia
Atomoxetine Ineffective
Ecitalopram Ineffective
Mirtazapine Improved sleep, irritability, sexually-inappropriate behaviors, aggression
Galanatmine Improved behavioral facets and socialization

 

Table 1: Medication Chart.

These promising results concords with those demonstrated in a naturalistic open-label study of mirtazapine in ASD where almost a third of subjects showed improvement across different domains including aggression, self-injury, irritability, hyperactivity, anxiety, depression, and, insomnia [4].

Anti-libidinal properties of mirtazapine helped sexually-inappropriate behaviors in ASD [5-6].

Cholinergic stimulation of central serotonergic subsystem with galantamine may enhance language and communication in autistic adults as shown in three cases [7]. A prospective open-label trial of galantamine in ASD showed it was well-tolerated and beneficial for interfering behaviors, particularly aggression, behavioral dyscontrol and inattention [8]. Recently, an RCT showed galantamine was effective and safe augmentative strategy for alleviating some of autism-related symptoms [9].

Such data accrue to open new venues of psychopharmacologic interventions in ASD that are both effective and well-tolerated.

Disclosures

Authors declare no conflicts of interests or financial affiliations with psychopharmaceutical companies or industry-sponsored research.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • International Conference on Social Sciences & Interdisciplinary Studies
    August 07-17 London, UK
  • 3rd International Conference on Autism
    Aug 21-22, 2017 Los Angeles, USA
  • 3rd International Conference on Epilepsy and Treatment
    September 01-17 Brussels, Belgium

Article Usage

  • Total views: 11766
  • [From(publication date):
    September-2015 - Jul 21, 2017]
  • Breakdown by view type
  • HTML page views : 7993
  • PDF downloads :3773
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version